Global Benign Prostatic Hyperplasia (BPH) Drugs Market Insights and Forecast to 2027

1 Study Coverage

• 1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type
  • 1.4.2 Alpha-Blocker
  • 1.4.3 Phosphodiesterase Type-5 Inhibitors
  • 1.2.4 Others
• 1.3 Market by Application
  • 1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application
  • 1.3.2 Hospitals
  • 1.3.3 Drugstores
  • 1.3.4 Others
• 1.4 Study Objectives
• 1.5 Years Considered

2 Executive Summary

• 2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts 2016-2027
• 2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Estimates and Forecasts 2016-2027
• 2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2016 VS 2021 VS 2027
• 2.4 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Sales
  • 2.4.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Sales (2016-2021)
  • 2.4.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Sales (2022-2027)
• 2.5 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Revenue
  • 2.5.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Revenue (2016-2021)
  • 2.5.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Regions by Revenue (2022-2027)
• 2.6 North America
• 2.7 Europe
• 2.8 Asia-Pacific
• 2.9 Latin America
• 2.10 Middle East & Africa

3 Competition by Manufacturers

• 3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers
  • 3.1.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers by Sales (2016-2021)
  • 3.1.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Share by Sales (2016-2021)
  • 3.1.3 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia (BPH) Drugs Sales in 2020
• 3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers
  • 3.2.1 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers by Revenue (2016-2021)
  • 3.2.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Share by Revenue (2016-2021)
  • 3.2.3 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2020
• 3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Manufacturers
• 3.4 Analysis of Competitive Landscape
  • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Geographical Distribution
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
  • 4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Sales by Type (2016-2021)
  • 4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Sales by Type (2022-2027)
  • 4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2027)
• 4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type
  • 4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Revenue by Type (2016-2021)
  • 4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Revenue by Type (2022-2027)
  • 4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2016-2027)
• 4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type
  • 4.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2016-2021)
  • 4.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2022-2027)

5 Market Size by Application

• 5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
  • 5.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Sales by Application (2016-2021)
  • 5.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Sales by Application (2022-2027)
  • 5.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2027)
• 5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application
  • 5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Revenue by Application (2016-2021)
  • 5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Revenue by Application (2022-2027)
  • 5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2016-2027)
• 5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application
  • 5.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2016-2021)
  • 5.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Application (2022-2027)

6 North America

• 6.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
  • 6.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2027)
  • 6.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2027)
• 6.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
  • 6.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2027)
  • 6.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2027)
• 6.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  • 6.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2027)
  • 6.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2027)
  • 6.3.3 U.S.
  • 6.3.4 Canada

7 Europe

• 7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
  • 7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2027)
  • 7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2017-2027)
• 7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
  • 7.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2027)
  • 7.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2017-2027)
• 7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  • 7.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2027)
  • 7.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2027)
  • 7.3.3 Germany
  • 7.3.4 France
  • 7.3.5 U.K.
  • 7.3.6 Italy
  • 7.3.7 Russia

8 Asia Pacific

• 8.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
  • 8.1.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2027)
  • 8.1.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2018-2027)
• 8.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
  • 8.2.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2027)
  • 8.2.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2018-2027)
• 8.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region
  • 8.3.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2018-2027)
  • 8.3.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2018-2027)
  • 8.3.3 China
  • 8.3.4 Japan
  • 8.3.5 South Korea
  • 8.3.6 India
  • 8.3.7 Australia
  • 8.3.8 Taiwan
  • 8.3.9 Indonesia
  • 8.3.10 Thailand
  • 8.3.11 Malaysia
  • 8.3.12 Philippines

9 Latin America

• 9.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
  • 9.1.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2027)
  • 9.1.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2027)
• 9.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
  • 9.2.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2027)
  • 9.2.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2027)
• 9.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  • 9.3.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2027)
  • 9.3.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2027)
  • 9.3.3 Mexico
  • 9.3.4 Brazil
  • 9.3.5 Argentina

6 Middle East and Africa

• 6.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
  • 6.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2027)
  • 6.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2027)
• 6.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
  • 6.2.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2027)
  • 6.2.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2016-2027)
• 6.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
  • 6.3.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2027)
  • 6.3.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2027)
  • 6.3.3 Turkey
  • 6.3.4 Saudi Arabia
  • 6.3.5 UAE

11 Company Profiles

• 11.1 Eli Lilly
  • 11.1.1 Eli Lilly Corporation Information
  • 11.1.2 Eli Lilly Overview
  • 11.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Description
  • 11.1.5 Eli Lilly Related Developments
• 11.2 GlaxoSmithKline
  • 11.2.1 GlaxoSmithKline Corporation Information
  • 11.2.2 GlaxoSmithKline Overview
  • 11.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Description
  • 11.2.5 GlaxoSmithKline Related Developments
• 11.3 Astellas Pharma
  • 11.3.1 Astellas Pharma Corporation Information
  • 11.3.2 Astellas Pharma Overview
  • 11.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Description
  • 11.3.5 Astellas Pharma Related Developments
• 11.4 Sanofi
  • 11.4.1 Sanofi Corporation Information
  • 11.4.2 Sanofi Overview
  • 11.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Description
  • 11.4.5 Sanofi Related Developments
• 11.5 Pfizer
  • 11.5.1 Pfizer Corporation Information
  • 11.5.2 Pfizer Overview
  • 11.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Description
  • 11.5.5 Pfizer Related Developments
• 11.6 Abbott
  • 11.6.1 Abbott Corporation Information
  • 11.6.2 Abbott Overview
  • 11.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Description
  • 11.6.5 Abbott Related Developments
• 11.7 Allergan
  • 11.7.1 Allergan Corporation Information
  • 11.7.2 Allergan Overview
  • 11.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Description
  • 11.7.5 Allergan Related Developments
• 11.8 TEVA
  • 11.8.1 TEVA Corporation Information
  • 11.8.2 TEVA Overview
  • 11.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Description
  • 11.8.5 TEVA Related Developments
• 11.9 Mylan
  • 11.9.1 Mylan Corporation Information
  • 11.9.2 Mylan Overview
  • 11.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Description
  • 11.9.5 Mylan Related Developments
• 11.10 Novartis
  • 11.10.1 Novartis Corporation Information
  • 11.10.2 Novartis Overview
  • 11.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Description
  • 11.10.5 Novartis Related Developments
• 11.1 Eli Lilly
  • 11.1.1 Eli Lilly Corporation Information
  • 11.1.2 Eli Lilly Overview
  • 11.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2016-2021)
  • 11.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Description
  • 11.1.5 Eli Lilly Related Developments

12 Value Chain and Sales Channels Analysis

• 12.1 Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Analysis
• 12.2 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
• 12.4 Benign Prostatic Hyperplasia (BPH) Drugs Sales and Marketing
  • 12.4.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels
  • 12.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
• 12.5 Benign Prostatic Hyperplasia (BPH) Drugs Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

• 13.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
• 13.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
• 13.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
• 13.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints

14 Key Findings in The Global Benign Prostatic Hyperplasia (BPH) Drugs Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Author Details